Literature DB >> 9655474

Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?

M Koga1, N Yuki, T Ariga, M Morimatsu, K Hirata.   

Abstract

The pharyngeal-cervical-brachial variant (PCB) of Guillain-Barré syndrome (GBS) has clinical features similar to those of botulism and diphtheria. Mizoguchi et al. (1994) [Mizoguchi, K., Hase, A., Obi, T., Matsuoka, H., Takatsu, M., Nishimura, Y., Irie, F., Seyama, Y., Hirabayashi, Y., 1994. Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 57, 1121-1123] reported a patient with PCB-like symptoms who had serum IgG anti-GT1a antibodies which did not cross-react with GQ1b. We assumed that PCB is associated with anti-GT1a antibodies that do not have reactivity to GQ1b and made a serological study of a PCB patient. We searched for PCB patients prospectively and found one with PCB. This patient had IgG anti-GT1a antibodies which were not absorbed with GQ1b in an absorption study, whereas IgG anti-GT1a antibodies from Fisher's syndrome patients were. The frequency of positive IgG anti-GT1a antibody did not differ in patients with and without bulbar palsy. Our findings indicate that IgG anti-GT1a antibodies which do not cross-react with GQ1b are specifically detectable in PCB and can be used as a diagnostic marker of PCB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655474     DOI: 10.1016/s0165-5728(98)00016-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

Review 1.  Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective.

Authors:  Graham M O'Hanlon; Roland W M Bullens; Jaap J Plomp; Hugh J Willison
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

2.  Anti-GT1a IgG in Guillain-Barré syndrome.

Authors:  M Koga; H Yoshino; M Morimatsu; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 3.  Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors:  Yusuf A Rajabally
Journal:  Neurotherapeutics       Date:  2022-06-01       Impact factor: 6.088

4.  Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study.

Authors:  Jong Kuk Kim; Jong Seok Bae; Dae-Seong Kim; Susumu Kusunoki; Jong Eun Kim; Ji Soo Kim; Young-Eun Park; Ki-Jong Park; Hyun Seok Song; Sun Young Kim; Jeong-Geun Lim; Nam-Hee Kim; Bum Chun Suh; Tai-Seung Nam; Min Su Park; Young-Chul Choi; Eun Hee Sohn; Sang-Jun Na; So Young Huh; Ohyun Kwon; Su-Yun Lee; Sung-Hoon Lee; Sun-Young Oh; Seong-Hae Jeong; Tae-Kyeong Lee; Dong Uk Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

Review 5.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

6.  Unilateral Abducens Nerve Palsy as an Early Feature of Multiple Mononeuropathy Associated with Anti-GQ1b Antibody.

Authors:  Ryuta Kinno; Hiroo Ichikawa; Hiroto Tanigawa; Kazuhiro Itaya; Mitsuru Kawamura
Journal:  Case Rep Neurol       Date:  2011-03-04

7.  Autoantibody screening in Guillain-Barré syndrome.

Authors:  Cinta Lleixà; Lorena Martín-Aguilar; Elba Pascual-Goñi; Teresa Franco; Marta Caballero; Noemí de Luna; Eduard Gallardo; Xavier Suárez-Calvet; Laura Martínez-Martínez; Jordi Diaz-Manera; Ricard Rojas-García; Elena Cortés-Vicente; Joana Turón; Carlos Casasnovas; Christian Homedes; Gerardo Gutiérrez-Gutiérrez; María Concepción Jimeno-Montero; José Berciano; Maria José Sedano-Tous; Tania García-Sobrino; Julio Pardo-Fernández; Celedonio Márquez-Infante; Iñigo Rojas-Marcos; Ivonne Jericó-Pascual; Eugenia Martínez-Hernández; Germán Morís de la Tassa; Cristina Domínguez-González; Cándido Juárez; Isabel Illa; Luis Querol
Journal:  J Neuroinflammation       Date:  2021-11-01       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.